Key result
CYP2C19 resistant alleles in ~28% of patients are linked to variable platelet inhibition by clopidogrel.
Why the study?
The study was conducted to determine the distribution of genetic polymorphisms in CYP2C19 in Iraqi patients and their role in inter-individual variability of clopidogrel efficacy.
Does CYP2C19 polymorphism affect platelet aggregation inhibition by clopidogrel in Iraqi patients at high risk of cardiovascular diseases?
Cohort (n=100)
Does CYP2C19 polymorphism affect platelet aggregation inhibition by clopidogrel in Iraqi patients at high risk of cardiovascular diseases?
In an Iraqi cohort, 28% of patients possessed clopidogrel-resistant CYP2C19 alleles (*2 and *3), highlighting the potential utility of genetic testing and VASP index monitoring to optimize antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
May support CYP2C19 testing in high-risk Iraqi patients; leaves open whether genotype-guided therapy improves outcomes.
OBJECTIVE: The current study was conducted to determine the distribution of genetic polymorphisms in CYP2C19 in Iraqi patients and their role in inter-individual variability of clopidogrel efficacy. PATIENTS AND METHODS: A prospective controlled study was done on 100 patients under high risk of cardiovascular diseases who started clopidogrel prophylactic therapy. Polymerase chain reaction-restriction fragment length polymorphism method was used to determine the existence of the CYP2C19 gene mutation. Vasodilator-stimulated phosphoprotein (VASP) index baseline besides one-month post-therapy was analyzed by dual-color flow cytometry analysis. RESULTS: Eight gene mutations of CYP2C19 were found (*1/*1), (*1/*2), (*1/*3), (*1/*8), (*1/*17), (*2/*2), (*2/*4), and (*3/*3) with higher prevalent CYP2C19*1 gene. Homozygous CYP2C19*1 allele was shown to be the rapid metabolizer comparing to the heterozygous CYP2C19*1 allele, whereas, CYP2C19*2 and CYP2C19*3 were resistant alleles and were present in 28% of patients. The analysis of VASP phosphorylation produces accurate inter-individual response variability in platelets inhibition by antiplatelet drugs. CONCLUSIONS: In vitro gene analysis and VASP index improve the clinical outcome of a patient candidate to clopidogrel as prophylaxis in cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Aga et al. (2020) conducted a cohort in High risk of cardiovascular diseases (n=100). CYP2C19 genetic polymorphisms (CYP2C19*2 and CYP2C19*3 alleles) vs. CYP2C19*1 allele was evaluated on Vasodilator-stimulated phosphoprotein (VASP) index. CYP2C19*2 and CYP2C19*3 resistant alleles were present in 28% of patients, contributing to inter-individual variability in platelet inhibition by clopidogrel.
Synapse has enriched 10 related papers. Consider them for comparative context: